New data from the Oxford COVID vaccine trial shows that the UK antidote is working well at Phase two, with defining percentages expected after Phase Three is complete.
Gino Martini, RPS Chief Scientist and the Science and Research Team at the Royal Pharmaceutical Society reflect on the role of pharmacy during COVID-19 in delivering accessible, safe and effective care for all.
European Public Health Association Executive Director, Dineke Zeegers Paget examines COVID-19 as a societal issue, not just a pandemic and argues that solidarity here is needed the most.
While the US and UK sealed their BioNTech and Pfizer vaccine deals within 24 hours of the new results, the European Commission took 3 days longer to secure their larger order of 300 million doses.
Yesterday, at 6:45am in the US, the Pfizer vaccine was revealed to be over 90% effective - so when will the successful drug be available for the UK to use?
Cecilia Van Cauwenberghe from Frost & Sullivan’s TechVision Group considers how the standard of healthcare for patients with diabetes is impacted by COVID-19.
Over 12 US Immigration and Customs Enforcement (ICE) detention centres had multiple outbreaks of infectious disease - due to withholding vaccines for adult and child migrants.
Professor Martin Michaelis and Dr Mark Wass of University of Kent’s School of Biosciences, explain why a herd immunity approach to COVID-19 would include great risk, potentially many deaths, and may simply not work.
Open Access Government explores the European Commission’s Department of Health and Food Safety’s response to the COVID-19 crisis and charts their next steps towards a vaccine for every European citizen.
Professor Martin Michaelis and Dr Mark Wass, School of Biosciences at University of Kent, explain the long and infamous history of human infection trials.
Scientists from the University of Oxford, joint with AstraZeneca, are hopeful that their vaccine, to protect against Covid-19, could be available as early as September.
